Boston-based TransCode Therapeutics is seeking strategic partners or a potential sale for its lead oncology asset, TTX-MC138, currently in Phase 2a clinical trials for colorectal cancer.
TransCode Therapeutics is actively seeking strategic alternatives for its lead oncology candidate, TTX-MC138, which is currently in Phase 2a clinical development for ctDNA-positive colorectal cancer. By engaging advisors to explore licensing, partnerships, or potential acquisitions, the company is signaling a shift toward maximizing shareholder value through external collaboration or divestiture.
The company is exploring strategic alternatives for its lead oncology asset, TTX-MC138, including licensing, development partnerships, and other strategic transactions.
TTX-MC138 is currently in Phase 2a clinical development for the treatment of ctDNA-positive colorectal cancer following curative-intent treatment.
TransCode Therapeutics has engaged advisors to evaluate strategic alternatives for its lead oncology candidate, TTX-MC138. The company is currently exploring licensing deals, development partnerships, or a potential acquisition to maximize value for its Phase 2a clinical program.
The company aims to explore options such as licensing, development partnerships, or other strategic transactions to advance its lead oncology asset, TTX-MC138.